Compare Incyte Corporation (INCY) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Verizon Communications Inc — how do they compare? Incyte Corporation trades at $117.86 (market cap $23.11B), while Verizon Communications Inc trades at $43.35 (market cap $181.64B). The key difference: Verizon Communications Inc is far larger — about 7.9× Incyte Corporation's market cap, and Verizon Communications Inc pays a 6.51% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VZ | |
|---|---|---|
Market Cap | $23.11B | $181.64B |
Sector | Health | Media |
52-Week High | $118.52 | $51.38 |
52-Week Low | $67.38 | $38.40 |
Enterprise Value | $19.13B | $369.14B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Verizon (VZ) trades at $43.51, down 0.19% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 10.63 and consistent earnings beats, including Q1 2026 EPS of $1.28 versus $1.21 expected. Recent news highlights a restructuring involving 3,000 job cuts and retail store divestitures to franchisees, aimed at improving efficiency. Cash flow from operations remains robust at $37.14 billion for 2025, supporting a dividend yield near 6.7%.
VZ offers value with low valuation multiples and a high dividend, but faces headwinds from intense wireless competition and execution risks in restructuring. Analyst consensus is a 'Hold' with a $48.06 price target, implying 10% upside. Key risks include debt levels and market saturation, while potential catalysts include successful cost-cutting and broadband growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
